Aravis


Aravis is a Switzerland based venture capital organisation managing two funds focused on life science (Aravis Biotech I & II) and a third fund focused on renewable energy (Aravis Energy I). Since 1995 the Aravis management team have invested over $600 million in more than 80 companies.

As well as providing venture capital backing, Aravis also takes a hands-on approach to highly promising companies offering a unique international network that combines decades of experience in science, operations and financing.

With a disciplined investment process and Aravis' hands on approach in supporting management, the companies that Aravis has invested in have shown a comparatively low failure rate and many have grown to become some of the leading companies in their fields.

News

26.07.10
NovImmune enters exclusive antibody licensing agreement with Genentech ...
30.06.10
Aravis Energy in the Swiss Press - Handelszeitung, 30 June 2010 ...
29.06.10
Omeros Successfully Unlocks Orphan GPCRs
Opportunity for Development of Unprecedented Number of Novel Drug Targets ...
14.06.10
Evolva Article in Roche Magazine RoSearch April 2010 ...
09.06.10
S*BIO Completes Enrollment of Patients in Phase 2 Clinical Trials for its JAK2 Inhibitor SB1518 ...
© 2008 Aravis SA  |  Lehfrauenweg 10   |  CH 8053 Zuerich  |  Tel. +41 43 499 20 00 | Fax +41 43 499 20 01  |  Disclaimer  |   Developed by Dogbytes Websolutions